IndiaFilingsIndiaFilings
India FlagRegister India Company
UAE FlagRegister UAE Company
USA FlagRegister USA Company

AAKANSHA PHARMACHEM LLP

LLPIN : AAF-9927|ROC: RoC-MumbaiActive
Last Updated On : 30-01-2023
LLPINAAF-9927
LLP NameAAKANSHA PHARMACHEM LLP
Number of Partners2
Number of Designated Partners2
ROC CodeRoC-Mumbai
Date of Incorporation18-03-2016
Registered AddressUdyog Kshetra, 2nd Floor, L.B.S. Marg, Mulund-Goregaon Link Road, Mulund (W), Mumbai Mumbai City Maharashtra 400080
Email ID[email protected]
Total Obligation of Contribution2,60,65,000
Main division of business activity to be carried out in India24
Description of main divisionManufacture of chemicals and chemical products
Date of last financial year end for Statement of Accounts and Solvency2022-03-31
Date of last financial year end for Annual Return filed31-03-2022
LLP StatusActive

Directors / Signatory Details

DIN / PANNameBegin Date
00066291RASHESH CHANDRAKANT GOGRI18-03-2016
01400047MULRAJ CHANDULAL GALA18-03-2016
AAKANSHA PHARMACHEM LLP is a Limited Liability Partnership (LLP) governed by the LLP Act, 2008. Registered under the Registrar of Companies RoC-Mumbai, it operates as a non-government entity. According to the Ministry of Corporate Affairs (MCA), this LLP was incorporated on 18-03-2016 and last updated on 30-01-2023. Its LLP Identification Number (LLPIN) is , and the registration number is . Currently, its eFiling status is listed as “Active” as per MCA records.
From a financial standpoint, AAKANSHA PHARMACHEM LLP has a total contribution of INR 2,60,65,000. Details of the latest financial filings, such as the Statement of Accounts and Solvency or Annual Returns, are unavailable, indicating limited publicly disclosed financial data.
The registered office address is Udyog Kshetra, 2nd Floor, L.B.S. Marg, Mulund-Goregaon Link Road, Mulund (W), Mumbai Mumbai City Maharashtra 400080. Correspondence or inquiries may be sent to the official email address, [email protected].
For those interested in further details, below are some frequently asked questions: